Furthermore, in terms of the treatment value of the combined treatment, the combination treatment of IFN-α and sorafenib is more applicable for tumor cells with normal IL-6 expression compared with the single treatment that could counteract the increased cell invasion ability related to either IFN-α or sorafenib treatment. This evidence concerns the gene IL6 and neoplasm.